Shares of Amarin (AMRN) have been struggling lately and have lost 5.4% over the past four weeks. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock ...

We expect investors to focus on the sales performance of Amarin Corporation’s AMRN sole marketed drug, Vascepa/Vazkepa, when it reports second-quarter 2025 results on July 30, before market open. The ...

Amarin's Vascepa drug had initial commercial success but is now facing steep revenue declines due to generic competition and limited U.S. market adoption. The company is running sizable losses, with ...

Amarin Corporation plc (NASDAQ:AMRN) is one of the best performing pharma stocks in 2025. Amarin Corporation plc (NASDAQ:AMRN) announced select unaudited 2025 financial highlights on January 8, ...

Detailed price information for Amarin Corp ADR (AMRN-Q) from The Globe and Mail including charting and trades.

Amarin Corporation Plc (NASDAQ:AMRN) on Tuesday entered into an exclusive long-term license and supply agreement with Recordati S.p.A., Italy, to commercialize Vazkepa (icosapent ethyl) in 59 ...

One stock that might be an intriguing choice for investors right now is Amarin Corporation plc (AMRN). This is because this security in the Medical - Biomed/Genetics space is seeing solid earnings ...

Amarin Corp (NASDAQ:AMRN) just reported results for the first quarter of 2024. Amarin Corp reported earnings per share of -1 cent. This was above the analyst estimate for EPS of -3 cents. The company ...